RESEARCH MONOGRAPH · KDC-MN-153

Valerian (Valeriana officinalis)

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

59/100

A botanical with consistent signal in animal models and frustratingly mixed human data

Valerian is the traditional sedative botanical thats had a complicated 30 years of research. The major bioactive candidates are the valepotriates (now mostly degraded in commercial preparations because they're unstable), valerenic acid (a sesquiterpene that appears to allosterically modulate GABA-A receptors at a benzodiazepine-distinct site), and various lignans. Mendel Friedman's group and others have done structural and pharmacological work on valerenic acid that suggests its the most likely primary actor, but the picture is mixed because different preparations have different chemistry depending on extraction method, plant variety, and storage.

The animal model literature is reasonably consistent: anxiolytic-like effects in elevated plus maze, sleep-promoting effects in EEG studies, GABA-A modulation demonstrable in vitro at concentrations that are physiologically plausible after oral administration.

The human clinical literature is much messier. Meta-analyses have been done multiple times with conflicting conclusions. Some show modest sleep onset latency improvements over placebo, others show essentially no effect. The 2010 Fernandez-San-Martin meta-analysis was reasonably positive, the 2020 Shinjyo meta-analysis was more mixed. The variability between studies almost certainly reflects the standardization problem (what's actually in the bottle varies dramatically across products) combined with the inherent difficulty of measuring subjective sleep endpoints in placebo-controlled trials.

What we like: the GABA-A site valerenic acid binds is genuinely different from the benzodiazepine site, which would be pharmacologically interesting if confirmed independently. The animal data is consistent. The safety profile of standard preparations is clean, no major hepatotoxicity signal despite decades of use.

What we dont like: the preparation standardization is genuinely bad. Different brands have wildly different valerenic acid content, which makes it almost impossible to give a coherent dose-response account. And the human efficacy data is inconsistent enough that we cant make strong claims about whether the molecule works at the population level even when standardized.

Mechanism: partially mapped (allosteric GABA-A modulation), but the relative contribution of valerenic acid versus other constituents isnt settled.

Sourcing: standardized extracts (typically targeting 0.8 to 1 percent valerenic acid) are available from research-grade botanical suppliers. The standardization helps but doesnt fully solve the consistency problem.

Worth understanding because the GABA-A allosteric story is real biology. Hedge on whether it works reliably in humans at the preparation level.

Evidence: 50
Mechanism: 60
Reliability: 45
Safety: 80
Sourcing: 55
Value: 70
Signal: 55
Staying power: 55

Plain-language summary Intrigue 45 / 100

Valerian (Valeriana officinalis) root is a traditional herbal sleep aid. Valerenic acid binds GABA-A receptors and may inhibit GABA reuptake. Clinical effects on sleep are modest in trials. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Botanical sedative / GABAergic herb

A perennial herb root traditionally used as a mild sedative, characterized by valerenic acid GABA-A modulation.

Abstract

Valeriana officinalis is a perennial herb whose root has been used for centuries as a mild sedative and anxiolytic. Active constituents include valerenic acid and related sesquiterpene acids, plus a complex mixture of valepotriates. Pharmacology includes GABA-A receptor modulation (valerenic acid binds the same receptor pocket as benzodiazepines but with different functional selectivity), modest adenosine A1 receptor agonism, and inhibition of GABA reuptake. Clinical evidence in primary insomnia is mixed; meta-analyses show modest improvements in sleep quality measures with effect sizes in the 0.2 to 0.4 range. Reported research dose ranges in the literature span 300 to 900 mg of standardized root extract.

Mechanism of action

GABA-A modulation through valerenic acid; modest adenosine A1 effects; GABA reuptake inhibition.

Reported research dose ranges

Reported research dose ranges in the literature span 300 to 900 mg of root extract.

References

Bent S, et al. Valerian for sleep: a systematic review and meta-analysis. Am J Med 2006.

Read the full monograph

Available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-153

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Valerian (Valeriana officinalis)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs